A Phase 1/2 interventional study of Corabotase and Placebo in Spasticity, sponsored by Ipsen. Recruiting at 81 sites in 14 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Ipsen · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Muscle Spasticity by Ipsen — 1 open to participants now, 1 under way, none of them phase 3. Muscle Spasticity · Ipsen.
Among the 15 studies in Muscle Spasticity by Ipsen, this one is one of 3 that started in 2021, is the only one in phase 1/2, and was the 14th registered.
626 studies on the registry are indexed under Muscle Spasticity; 131 are open to participants now.
Browse Muscle Spasticity studies →1 of the 15 studies in Muscle Spasticity by Ipsen is open now, in 12 countries.
By country, each count listing its studies:
Of the 88 Muscle Spasticity studies recruiting now, 29 (33%) set no upper age limit and 47 (53%) stop at 75 or younger; 34 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2021.
This study's planned enrollment of 240 is above the median of 36 across 477 interventional studies indexed under Muscle Spasticity.
Median enrollment 189 across the 6 interventional studies, 150 across the 9 observational. Of the 14 that completed or were terminated, 2 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ipsen is the lead sponsor of 291 studies on the registry; 19 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Muscle Spasticity by Ipsen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the safety and efficacy of increasing doses of Corabotase (also known as IPN10200) with the aim to evaluate the Pharmacodynamics (PD) profile of Corabotase and to establish the total Corabotase doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Does not have any fixed contractures as defined by:
Male participants must agree that, if their partner is at risk of becoming pregnant, they will use an effective method of contraception. The participants must agree to use the contraception during the whole period of the study.
A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: Is a woman of non- (WONCBP) or is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method (until the end of the study). The investigator should evaluate the potential for contraceptive method failure in relationship to the first dose of study intervention. A WOCBP must have a negative highly sensitive pregnancy test.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One single administration of study medication (Corabotase, Dysport or placebo) will be injected in a dose-escalation manner. Dose-escalation will include several cohorts.
Biological: Corabotase · Drug: Placebo · Biological: Dysport
Two fixed doses of Corabotase will be administrated as a single injection into several muscle groups of the upper limb. Participants will be randomised in the ratio of 3:3:2 (total Corabotase dose 1: 30 participants; total Corabotase dose 2: 30 participants; Dysport: 20 participants)
Biological: Corabotase · Biological: Dysport
One single injection of study medication will be administered locally into several muscle groups of the upper limb. Participants will be randomized in the ratio of 2:1 (Total Corabotase dose: 30 participants; placebo: 15 participants, resulting in a total of 45 participants in Stage 3). Or Participants will be randomized in the ratio of 3:1 (Corabotase lower dose: 30 participants; placebo: 10 participants, then Corabotase higher dose: 30 participants; placebo: 10 participants, resulting in a total of 80 participants in Stage 3).
Biological: Corabotase · Drug: Placebo
Powder and solvent for solution for injection
Also known as: IPN10200
Powder and solvent for solution for injection
Powder for solution for injection
Percentage of participants with treatment emergent adverse events (TEAEs).
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: From baseline until the end of study (9 months)
Percentage of participants with adverse events of special interest (AESI).
Time frame: From baseline until the end of study (9 months)
Change from baseline in vital sign parameter (blood pressure)
Time frame: 9 months
Change from baseline in vital sign parameter (Heart rate)
Time frame: 9 months
Change from baseline in clinical laboratory test results.
Number and percentage of participants with low, normal or high values and normal or abnormal examinations will be presented.
Time frame: 9 months
Presence of IPN10200 and BoNT-A antibodies (binding and neutralising)
Time frame: From baseline until the end of study (9 months)
Change from baseline in physical examination findings.
Number of Participants with change in physical examination findings
Time frame: 9 months
Change from Baseline to all post-treatment visits in Modified Ashworth scale (MAS) score in the Primary target muscle group (PTMG)
MAS is a scale to assess muscle tone in the injected muscles. The muscle tone will be rated as per grading from 0 to 4, there 0 =No increase in muscle tone and 4 =Affected part(s) rigid in flexion or extension.
Time frame: from baseline until the end of study (9 months)
Change from Baseline to post-treatment Day 29 in MAS score in the PTMG.
If PD profile of IPN10200 in dose escalation indicates a peak of effect different than Day 29, the endpoint will be modified accordingly)
Time frame: From baseline until post-treatment Day 29
Change from Baseline in MAS score in all injected muscle Groups
Time frame: From baseline until the end of study (9 months)
Time to onset - time to the response to treatment (a reduction of at least one grade in the MAS score).
Time frame: From baseline until the end of study (9 months)
Peak of effect - maximal decrease in the MAS score from Baseline.
Time frame: From baseline until the end of study (9 months)
Time to peak - time to reach the peak of effect (maximal decrease in the MAS score from Baseline).
Time frame: From baseline until the end of study (9 months)
Duration of effect - duration between time to onset and last timepoint with a response to Treatment.
Time frame: From baseline until the end of study (9 months)
Response to treatment as measured by at least one grade reduction in MAS score in the PTMG from Baseline
Time frame: From baseline until the end of study (9 months)
Response to treatment as measured by at least one grade reduction in MAS score in all injected muscles from Baseline
Time frame: From baseline until the end of study (9 months)
Physician's Global Assessment (PGA) score of overall treatment response
The PGA is a 9-point scale (from -4= markedly worse to +4=markedly improved) used to assess global overall treatment response by the investigator.
Time frame: From baseline until the end of study (9 months)
Patient Global Impression of Change in the Spastic Clinical Pattern using specific scale (PGI-c)
PGI-C is a scale to assess global impression of change in the spastic clinical pattern using a 7-point Likert scale (from -3: very much worse to +3: very much improved) by answering a specific question
Time frame: from baseline until the end of study (9 months)
Change from Baseline in the Disability Assessment Scale (DAS)
The DAS will be used to assess the effect of upper limb spasticity on hygiene, dressing, limb position and pain. Participants will be assessed in an interview format.
Time frame: From baseline until the end of study (9 months)
Reduction of pain in the shoulder (adducted/rotated pattern) using the Numeric Rating Scale
Time frame: From baseline until the end of study (9 months)
The number and percentage of participants with presence of IPN10200 and BoNT-A antibodies and titres (binding and neutralising)
Time frame: At baseline
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Data sharing details ↗ · www.ipsen.com
No publications or documents are linked to this record.
Started Apr 2021 (actual). Primary completion is estimated for Mar 2029, 95 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.